Login
Companies $CLNN
$3.65 -$0.01 (0.27%) After hours
Clene Inc. logo

Clene Inc.

clene.com

What Do They Do?

Develops nanocrystal drug candidates for people with central nervous system disorders and sells mineral dietary supplements through a subsidiary and licensee.

How Do They Make Money?

Clene earns money from dietary supplement sales and royalties on supplement sales. Commercial customers pay upon receipt, while online retail customers prepay; the company fulfills supplement orders by delivery.

revenue
SegmentShareRevenue
Product
Sold outright

60%
FY2022: 70%
Royalty
Licensed

41%
FY2022: 30%

Who Are Their Customers?

Supplement customers buy through dOrbital or 4Life: dOrbital sells rMetx, while 4Life sells Zinc Factor under a supply agreement and markets Gold Factor under an exclusive worldwide license.

Do Revenues Turn Into Profits?

No. It lost $26.2M in FY2025.

Operating income, FY2025
−11542% of revenue
▲ +30% (Loss) vs FY2024 (−$33.1M, −9676%)
Net income, FY2025
−13087% of revenue
▲ +34% (Loss) vs FY2024 (−$39.4M, −11520%)
Free cash flow, FY2025
−9293% of revenue
▲ +13% (Loss) vs FY2024 (−$21.3M, −6240%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +273%
vs $15K in Q3 FY2025
Net income
▲ Turned profitable
vs −$8.8M in Q3 FY2025
Product share of revenue vs 0.0% in Q3 FY2025

Shrinking. Revenue fell 72% in 4 years, from $723K in FY2021 to $200K in FY2025, about 27% a year.

Revenue over time
Product Royalty
$1M$500K$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support